ARTICLE | Clinical News

Cell Genesys preclinical data

November 7, 1994 8:00 AM UTC

CEGE (Foster City, Calif.) published the design of its anti-HIV T cells in Blood, and showed that they kill HIV-infected cells in laboratory experiments.

The company achieved efficient retroviral transfer into the killer cells, which typically resist gene transduction. The cells express universal, or major histocompatibility complex-unrestricted, T cell receptors specific for HIV. They have an antigen-binding domain comprised of either CD4 or a single chain antibody to gp41, and the cytoplasmic domain of the zeta portion of a receptor on killer T cells. ...